Figure 5
From: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
Westernblot analysis of eEF-1α. A eEF-1α in sensitive and resistant cells. Lane 1. SCLCB, lane 2: SCLCBC, lane 3: SR-2, lane 4: SCLC1. The signal intensity of the resistant cell line SCLCBC and SR-2 are much greater than their sensitive cells SCLCB and SCLC1 counterpart. B eEF-1α in SR-2 cell line. Lane 1: control, lane 2&3: SR-2 treated with 0.5 and 10 ug/ml of cisplatin respectively. Similar signal intensity are seen compared to control, lane 4&5: SR-2 treated with 10 ng and 50 ng/ml of CCI-779 respectively. There is no change in signal intensity of eEF-1α at 10 ng of CCI-779, but decreased after exposure to 50 ng/ml of CCI-779, lane 6: SR-2 treated with 10 ug/.ml of cisplatin with CCI-779 50 ng/ml, the signal intensity also less and similar to those treated with CCI-779 alone. C eEF-1α in SCLCBC. Lane 1: control, lane 2&3 SCLCBC treated with 0.5 ug and 10 ug/ml of cisplatin respectively. Similar signal intensity of eEF-1α is seen compared to control, lane 4&5: SR-2 treated with 10 ng and 50 ng/ml of CCI-779 respectively, there is no changes in signal intensity at 10 ng/ml of CCI-779, but decreased at 50 ng/ml of CCI-779, lane 6 SCLCBC treated with 10 ug/ml of cisplatin with CCI-779 50 ng/ml. The signal intensity is less and similar to those treated with CCI-779 alone.